Substance use in older HIV-infected patients

Current Opinion in HIV and AIDS

Volumn 9, Issue 4, 2014, Pages 317-324

  Edelman, E Jennifer ^a,b   Tetrault, Jeanette M ^a   Fiellin, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

HIV; older adults; substance related disorders

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; CANNABIS; CENTRAL STIMULANT AGENT; DIAMORPHINE; OPIATE;

ALCOHOL ABUSE; CANNABIS ADDICTION; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SUBSTANCE USE; TOBACCO DEPENDENCE; AGING; ALCOHOLISM; COMPLICATION; SMOKING; SUBSTANCE-RELATED DISORDERS;

AGING; ALCOHOLISM; HIV INFECTIONS; HUMANS; SMOKING; SUBSTANCE-RELATED DISORDERS;

EID: 84902254646     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000069     Document Type: Review

References (130)

1. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382:1575-1586.
2. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382:1564-1574.
3. Hser YI, Huang D, Brecht ML, et al. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis 2008; 27:13-21.
4. Green TC, Kershaw T, Lin H, et al. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend 2010; 110:208-220.
5. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychol Addict Behav 2013; 27:1050-1058.
6. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352:596-607.
7. Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry 2001; 58:729-736.
8. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002; 63:179-186.
9. Phillips SJ, Freedberg KA, Traphagen ET, et al. Screening for alcohol problems in HIV-infected primary care patients. J Gen Int Med 2001; 16:165.
10. Petry NM. Alcohol use in HIV patients: what we don't know may hurt us. Int J STD AIDS 1999; 10:561-570.
11. Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001; 16:83-88.
12. Lefevre F, O'Leary B, Moran M, et al. Alcohol consumption among HIVinfected patients. J Gen Intern Med 1995; 10:458-460.
13. Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 2004; 18 (Suppl 1):S43-S48.
14. McGinnis KA, Justice AC, Kraemer KL, et al. Comparing alcohol screening measures among HIV-infected and-uninfected men. Alcohol Clin Exp Res 2013; 37:435-442.
15. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and doseresponse association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005; 29:1190-1197.
16. Cook RL, McGinnis KA, Kraemer KL, et al. Intoxication before intercourse and risky sexual behavior in male veterans with and without human immunodeficiency virus infection. Med Care 2006; 44 (8 Suppl 2):S31-S36.
17. Lim JK, Tate JP, Fultz SL, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis c virus-infected, and uninfected patients. Clin Infect Dis 2014; 58:1449-1458.
18. Scott-Sheldon LA, Walstrom P, Carey KB, et al. Alcohol use and sexual risk behaviors among individuals infected with HIV: a systematic review and meta-analysis 2012 to early 2013. Curr HIV/AIDS Rep 2013; 10:314-323.
19. Lin JC, Guerrieri JG, Moore AA. Drinking patterns and the development of functional limitations in older adults: longitudinal analyses of the health and retirement survey. J Aging Health 2011; 23:806-821.
20. Jeong HG, Kim TH, Lee JJ, et al. Impact of alcohol use on mortality in the elderly: results from the Korean Longitudinal Study on Health and Aging. Drug Alcohol Depend 2012; 121:133-139.
21. Jonas DE, Garbutt JC, Amick HR, et al. Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U. S. Preventive Services Task Force. Ann Intern Med 2012; 157:645-654.
22. Moore AA, Blow FC, Hoffing M, et al. Primary care-based intervention to reduce at-risk drinking in older adults: a randomized controlled trial. Addiction 2011; 106:111-120.
23. Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 2012; 36:318-324.
24. Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014; 174:70-77.
25. Litten RZ, Ryan ML, Fertig JB, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013; 7:277-286.
26. Brennan C. Smoking can have negative impact on immune response to HAART. HIV Clin 2013; 25:6-9.
27. Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav 2012; 36:75-85.
28. Royce RA, Winkelstein W Jr. HIV infection, cigarette smoking and CD4 T-lymphocyte counts: preliminary results from the San Francisco Men's Health Study. AIDS 1990; 4:327-333.
29. Park LP, Margolick JB, Giorgi JV, et al. Influence of HIV-1 infection and cigarette smoking on leukocyte profiles in homosexual men. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1992; 5:1124-1130.
30. Kabali C, Cheng DM, Brooks DR, et al. Recent cigarette smoking and HIV disease progression: no evidence of an association. AIDS Care 2011; 23:947-956.
31. Montarroyos UR, Miranda-Filho DB, Cesar CC, et al. Factors related to changes in CD4 T-cell counts over time in patients living with HIV/AIDS: a multilevel analysis. PLoS One 2014; 9:e84276.
32. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012; 26:1017-1025.
33. Browning KK, Wewers ME, Ferketich AK, Diaz P. Tobacco use and cessation in HIV-infected individuals. Clin Chest Med 2013; 34:181-190.
34. De P, Farley A, Lindson N, Aveyard P. Systematic review and meta-analysis: influence of smoking cessation on incidence of pneumonia in HIV. BMC Med 2013; 11:15.
35. Winstone TA, Man SF, Hull M, et al. Epidemic of lung cancer in patients with HIV infection. Chest 2013; 143:305-314.
36. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS 2013; 27:1949-1957.
37. Bertisch B, Franceschi S, Lise M, et al. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol 2013; 178:877-884.
38. Fitch KV, Looby SE, Rope A, et al. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS 2013; 27:49-57.
39. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013; 56:727-734.
40. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14:824-835.
41. Horvath KJ, Eastman M, Prosser R, et al. Addressing smoking during medical visits: patients with human immunodeficiency virus. Am J Prev Med 2012; 43 (5 Suppl 3):S214-S221.
42. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. Arch Intern Med 2012; 172:837-844.
43. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012; 10:CD008286.
44. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11:CD000146.
45. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012; 12:CD009670.
46. Moscou-Jackson G, Commodore-Mensah Y, Farley J, Digiacomo M. Smoking-cessation interventions in people living with HIV infection: a systematic review. J Assoc Nurses AIDS Care 2014; 25:32-45.
47. Moadel AB, Bernstein SL, Mermelstein RJ, et al. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr 2012; 61:208-215.
48. Matthews AK, Conrad M, Kuhns L, et al. Project Exhale: preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDS 2013; 27:22-32.
49. Cropsey KL, Hendricks PS, Jardin B, et al. A pilot study of screening, brief intervention, and referral for treatment (SBIRT) in nontreatment seeking smokers with HIV. Addict Behav 2013; 38:2541-2546.
50. Niaura R, Chander G, Hutton H, Stanton C. Interventions to address chronic disease and HIV: strategies to promote smoking cessation among HIVinfected individuals. Curr HIV/AIDS Rep 2012; 9:375-384.
51. Vidrine DJ, Marks RM, Arduino RC, Gritz ER. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res 2012; 14:106-110.
52. Gritz ER, Danysh HE, Fletcher FE, et al. Long-term outcomes of a cell phonedelivered intervention for smokers living with HIV/AIDS. Clin Infect Dis 2013; 57:608-615.
53. Pedrol-Clotet E, Deig-Comerma E, Ribell-Bachs M, et al. Bupropion use for smoking cessation in HIV-infected patients receiving antiretroviral therapy. Enferm Infecc Microbiol Clin 2006; 24:509-511.
54. Tornero C, Mafe C. Varenicline and antiretroviral therapy in patients with HIV. J Acquir Immune Defic Syndr 2009; 52:656.
55. Ferketich AK, Diaz P, Browning KK, et al. Safety of varenicline among smokers enrolled in the lung HIV study. Nicotine Tob Res 2013; 15: 247-254.
56. Cui Q, Robinson L, Elston D, et al. Safety and tolerability of varenicline tartrate (Champix((R))/Chantix((R))) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS 2012; 26:12-19.
57. Gossop M, Moos R. Substance misuse among older adults: a neglected but treatable problem. Addiction 2008; 103:347-348.
58. Simoni-Wastila L, Yang HK. Psychoactive drug abuse in older adults. Am J Geriatr Pharmacother 2006; 4:380-394.
59. SAMHSA OoASSAaMHSA. Illicit drug use among older adults: U. S. Department of Health and Human Services 2011.
60. SAMHSA OoASSAaMHSA. Drug-related Emergency Department visits involving pharmaceutical misuse or abuse by older adults: 2009: U. S. Department of Health and Human Services 2009.
61. Top 25 U. S. Pharmaceutical Products by Dispensed Prescriptions. 2013. http://www. imshealth. com/deployedfiles/ims/Global/Content/Corporate/ Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011% 20Top-line%20Market%20Data/Top-Products-by-RX. pdf. [Accessed 10 February 2014]
62. Smith AJ, Tett SE. Improving the use of benzodiazepines: is it possible? A nonsystematic review of interventions tried in the last 20 years. BMC Health Serv Res 2010; 10:321.
63. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 2004; 3:485-493.
64. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Practice 2011; 61:e573-e578.
65. Gould RL, Coulson MC, Patel N, et al. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry 2014; 204:98-107.
66. Parr JM, Kavanagh DJ, Cahill L, et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 2009; 104:13-24.
67. Kalapatapu RK, Sullivan MA. Prescription use disorders in older adults. Am J Addict 2010; 19:515-522.
68. Gatch MB, Kozlenkov A, Huang RQ, et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology 2013; 38:2373-2384.
69. Davis GP, Surratt HL, Levin FR, Blanco C. Antiretroviral medication: an emerging category of prescription drug misuse. Am J Addict 2013; doi: 10. 1111/j. 1521-0391. 2013. 12107. x. [Epub ahead of print]
70. Surratt HL, Kurtz SP, Cicero TJ, et al. Antiretroviral medication diversion among HIV-positive substance abusers in South Florida. Am J Public Health 2013; 103:1026-1028.
71. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club-and street-based populations. Pain Med 2007; 8:171-183.
72. Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One 2013; 8:e76635.
73. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. In: H-46, N. S., editor. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
74. Prentiss D, Power R, Balmas G, et al. Patterns of marijuana use among patients with HIV/AIDS followed in a public healthcare setting. J Acquir Immune Defic Syndr 2004; 35:38-45.
75. Abrams DI. Potential interventions for HIV/AIDS wasting: an overview. J Acquir Immune Defic Syndr 2000; 25 (Suppl 1):S74-S80.
76. de Jong BC, Prentiss D, McFarland W, et al. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr 2005; 38: 43-46.
77. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Ret Eye Res 2008; 27:501-526.
78. D'Souza G, Matson PA, Grady CD, et al. Medicinal and recreational marijuana use among HIV-infected women in the Women's Interagency HIV Study (WIHS) cohort, 1994-2010. J Acquir Immune Defic Syndr 2012; 61:618-626.
79. Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167:221-228.
80. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012; 307:173-181.
81. Kirk GD, Merlo C, P OD, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110.
82. Callaghan RC, Alleback PAS. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 2012; 24:1811-1820.
83. Mehra R, Moore BA, Crothers K, et al. The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 2006; 166:1359-1367.
84. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 2012; 109:E2657-E2664.
85. Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 1999; 149:794-800.
86. Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIVpositive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 2007; 45:545-554.
87. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 169:805-812.
88. Armstrong GL. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med 2007; 167:166-173.
89. Rosen D, Hunsaker A, Albert SM, et al. Characteristics and consequences of heroin use among older adults in the United States: a review of the literature, treatment implications, and recommendations for further research. Addict Behav 2011; 36:279-285.
90. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21:149-179.
91. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010; 376:367-387.
92. Melo AC, Caiaffa WT, Cesar CC, et al. Utilization of HIV/AIDS treatment services: comparing injecting drug users and other clients. Cadernos de Saude Publica 2006; 22:803-813.
93. Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013; 30:613-628.
94. Kao D, Bucher Bartelson B, Khatri V, et al. Trends in reporting methadoneassociated cardiac arrhythmia, 1997-2011: an analysis of registry data. Ann Intern Med 2013; 158:735-740.
95. Schmittner J, Krantz MJ. High-dose methadone and QTc prolongation: strategies to optimize safety. J Opioid Manag 2006; 2:49-55.
96. Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 2011; 56 (Suppl 1):S62-S67.
97. Tetrault J, Tate JP, Edelman E, Gordon A, Lo Re V, Fiellin L et al. Use and Safety of Buprenorphine in HIV-infected and Uninfected Opioid Dependent Patients. Society of General Internal Medicine Annual Meeting; Denver, CO2013.
98. Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIVinfected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011; 56 (Suppl 1):S33-S38.
99. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/ naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011; 56 (Suppl 1): S22-S32.
100. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/ naloxone and HIV clinical care. Clin Infect Dis 2006; 43 (Suppl 4):S184-S190.
101. Tetrault JM, Moore BA, Barry DT, et al. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat 2012; 43:433-439.
102. Skeer MR, Mimiaga MJ, Mayer KH, et al. Patterns of substance use among a large urban cohort of HIV-infected men who have sex with men in primary care. AIDS Behav 2012; 16:676-689.
103. Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health 2013; 103:1457-1467.
104. Lyons A, Pitts M, Grierson J. Methamphetamine use in a nationwide online sample of older Australian HIV-positive and HIV-negative gay men. Drug Alcohol Rev 2013; 32:603-610.
105. Moore DJ, Blackstone K, Woods SP, et al. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral nonadherence. AIDS Care 2012; 24:1504-1513.
106. Baum MK, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr 2009; 50:93-99.
107. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22:1355-1363.
108. Shoptaw S, Stall R, Bordon J, et al. Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study. Int J STD AIDS 2012; 23:576-580.
109. Rasbach DA, Desruisseau AJ, Kipp AM, et al. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. AIDS Care 2013; 25:109-117.
110. Buch S, Yao H, Guo M, et al. Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV Res 2012; 10:425-428.
111. Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIVassociated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011; 44:102-110.
112. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010; 122:2558-2569.
113. Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci 2003; 73:129-140.
114. Mayer KH, Skeer MR, O'Cleirigh C, et al. Factors associated with amplified HIV transmission behavior among American men who have sex with men engaged in care: implications for clinical providers. Ann Behav Med 2014; 47:165-171.
115. Heath J, Lanoye A, Maisto SA. The role of alcohol and substance use in risky sexual behavior among older men who have sex with men: a review and critique of the current literature. AIDS Behav 2012; 16:578-589.
116. Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev 2012; 5:320-331.
117. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008; 27:309-317.
118. Pani PP, Trogu E, Vacca R, et al. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010; CD007024.
119. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007; CD006306.
120. Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008; CD006754.
121. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database Syst Rev 2011; CD002950.
122. Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther 2012; 91:60-70.
123. McClure EA, Gipson CD, MalcolmRJ, et al. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs 2014; 28:95-106.
124. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013; 70:1338-1346.
125. Elkashef A, Kahn R, Yu E, et al. Topiramate for the treatment of methamphetamine addiction: a multicenter placebo-controlled trial. Addiction 2012; 107:1297-1306.
126. Somoza EC, Winship D, Gorodetzky CW, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013; 70:630-637.
127. Mariani JJ, Levin FR. Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am 2012; 35:425-439.
128. Sullivan LE, Botsko M, Cunningham CO, et al. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011; 56 (Suppl 1):S54-S61.
129. Faragon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read 2003; 13:433-434; 7-41, 46-50.
130. Drainoni ML, Farrell C, Sorensen-Alawad A, et al. Patient perspectives of an integrated program of medical care and substance use treatment. AIDS Patient Care STDS 2014; 28:71-81.